Bone Marrow Aspiration clinical trials
6 indexed studies · 2 currently recruiting
- Active not recruitingPHASE2
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
This study looks at a new drug, revumenib, with chemotherapy for babies and young children (under 6) with a type of leukaemia that has come back or isn't responding well to treatment, especially if they have a specific gene change.
For: Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageUnited States · Canada - Active not recruitingPHASE2
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
This study looks at a new drug, enasidenib, for children and young people (aged 2-21) with a type of blood cancer called Acute Myeloid Leukemia (AML) that has come back or is hard to treat. It focuses on those with a specific genetic change in their cancer cells.
For: Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid LeukemiaUnited States · Canada - RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This study looks at new ways to treat a serious type of blood cancer called AML in people aged 18-59. It compares standard treatment with newer drug combinations to see if they work better at shrinking the cancer.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - Active not recruitingPHASE3
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
This study looks at new ways to treat a type of cancer called rhabdomyosarcoma, which can be aggressive. We're testing if adding a drug called vinorelbine to standard treatment, and then using a 'maintenance' therapy, helps stop the cancer from coming back.
For: Alveolar Rhabdomyosarcoma · Botryoid-Type Embryonal Rhabdomyosarcoma · Embryonal RhabdomyosarcomaUnited States · Australia · Canada - Active not recruitingPHASE2
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
This study looks at combining existing treatments for high-risk neuroblastoma to see if it works better. It's for children and young people who have already had intensive therapy, to help prevent the cancer from coming back.
For: Ganglioneuroblastoma, Nodular · NeuroblastomaUnited States · Australia · Canada